Lifestyle changes to prevent recurring C. difficile infection
Part of Infections clinical trials.
This study tests whether specific lifestyle changes during treatment for C. difficile infection (a serious gut bacteria infection) can help prevent it from coming back. You'll receive standard antibiotic treatment and follow a controlled diet while researchers track your recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have a first or non-recurring C. difficile infection confirmed by lab test
- Be starting or currently receiving standard antibiotic treatment (fidaxomicin or vancomycin)
- Never had advanced treatments for C. difficile like fecal transplant or prolonged antibiotics
- Be able to follow a prepared study diet and stop taking probiotic supplements
- Not be hospitalized or in a nursing facility when your antibiotic treatment ends
- Be able to provide stool samples for testing throughout the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking a capsule form of fecal microbiota transplant (FMT) can help adults with their first C. difficile infection—or a first relapse—get better and reduce repeat episodes. Participants also take specific antibiotics for C. difficile as part of the study process.
This trial compares three treatments for a severe diarrhea infection called C. diff: a fecal transplant (putting healthy donor stool into your gut), a newer antibiotic called fidaxomicin, and an older antibiotic called vancomycin. The goal is to see which works best and prevents the infection from coming back.
This study tests a new live bacteria product (EXL01) given with vancomycin to prevent C. diff from coming back. It is for people who have already had C. diff two or more times and are at high risk of another infection.
This study tests whether adding a common bile acid (ursodeoxycholic acid) to your regular C. diff treatment can help stop the infection from coming back. The goal is to see if this extra medicine reduces the chance of recurrence.
This study tests a new antibody (AZD5148) to prevent C. diff infection from coming back. If you have a current C. diff infection and are being treated with antibiotics, you may be able to join.
This trial tests a new medicine called VE303, a live bacterial therapy, to prevent C. diff infections from coming back. It is for people who have had C. diff at least once in the last 6 months, or who are at high risk for a repeat infection due to age or other health problems.
Hear when a new Clostridioides Difficile Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.